Kaposi sarcoma (KS) is a multi-focal angioproliferative disease driven by infection of cells by Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV/HHV8 infection activates numerous sequential and parallel signaling pathways creating an angiogenic-inflammatory state that leads to the development of Kaposi sarcoma. These pathways can be grouped into KSHV/HHV8-specific pathways and cellular growth/angiogenic pathways that are pirated by KSHV/HHV8. Advances in our understanding of the pathogenesis of KS parallel the clinical development of signal transduction inhibitors. This chapter reviews the signaling pathways active in KSHV/HHV8-infected cells and discusses the use of clinical inhibitors of these pathways in the treatment of KS.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)